Research Into The State Of Innovation In Highly Prevalent Chronic Diseases
By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL
Dave Thomas is the managing director for industry research and analysis at the Biotechnology Innovation Organization (BIO). During the 2018 BIO International Convention and Conference in Boston, I had the opportunity to interview Thomas at the BIO Buzz Center. Thomas shares some highlights on what he and his colleagues have been researching and publishing reports on, such as chronic diseases (i.e., depression, pain, and addiction), and emerging therapeutics company investment deal trends. When studying VC, Thomas noted a disproportionate amount of funding going to oncology and rare disease, and less funding going into the highly prevalent chronic diseases. Wanting to investigate if this was a widespread issue beyond the VC stage, BIO decided to do a deep dive on each of the indications that are in the chronic disease space. Future research plans include diabetes, obesity, Alzheimer’s and Parkinson’s diseases. Below is my short Buzz Center video interview with Thomas, as well as links to the current published reports.
The State Of Innovation In Highly Prevalent Chronic Diseases Volume I: Depression Therapeutics